# ClinicalTrials.gov record NCT02404376

> PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct02404376-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02404376-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02404376-exenatide-v1.json
- Content SHA-256: `b731e527402dc5f901185b9e3a9c2ad7056eb83150dd603e098fbfdfdc1fb49a`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02404376 ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02404376 at 2026-07-30T20:20:00.368Z. Its registry update date was 2020-11-03, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02404376-2020-11-03-be534246b18f`](#source-ctg-observation-nct02404376-2020-11-03-be534246b18f))

## Sources

<a id="source-ctg-observation-nct02404376-2020-11-03-be534246b18f"></a>
- **ClinicalTrials.gov record NCT02404376 · retained source version 2020-11-03:be534246b18f61d95606ad83c659b346c82744e02b1672de711e542d1ffcae41** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02404376) (`ctg-observation-nct02404376-2020-11-03-be534246b18f`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02404376." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02404376-exenatide-v1.json SHA-256: b731e527402dc5f901185b9e3a9c2ad7056eb83150dd603e098fbfdfdc1fb49a.